Importance of Candida infection and fluconazole resistance in women with vaginal discharge syndrome in Namibia.
Antifungal susceptibility testing
Candida albicans
Namibia
Non-albicans Candida species
Sexually transmitted infections
Sub-Saharan Africa
Vaginal discharge syndrome
Journal
Antimicrobial resistance and infection control
ISSN: 2047-2994
Titre abrégé: Antimicrob Resist Infect Control
Pays: England
ID NLM: 101585411
Informations de publication
Date de publication:
15 08 2022
15 08 2022
Historique:
received:
31
03
2022
accepted:
27
07
2022
entrez:
15
8
2022
pubmed:
16
8
2022
medline:
18
8
2022
Statut:
epublish
Résumé
Vaginal discharge syndrome (VDS) is a common condition. Clinical management targets sexually transmitted infections (STIs) and bacterial vaginosis (BV); there is limited focus on Candida infection as cause of VDS. Lack of Candida treatment coverage and, if present, antifungal resistance may result in VDS treatment failure. This study aimed to determine the prevalence of Candida infection, antifungal resistance, and coinfections in Namibian women with VDS. A cross-sectional study was performed using 253 vaginal swabs from women with VDS in Namibia. Demographic data was collected, and phenotypic and molecular detection of Candida species was performed followed by fluconazole susceptibility testing of Candida isolates. BV was diagnosed using Nugent score microscopy; molecular detection of Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis was performed. Candida species was detected in 110/253 women (43%). Ninety women (36%) had Candida albicans and 24 (9.5%) had non-albicans Candida species. The non-albicans species detected were 19 (17%) Candida glabrata, 4.0 (3.5%) Candida krusei, and 1.0 (0.9%) Candida parapsilosis. Candida albicans were more frequently isolated in younger (p = 0.004) and pregnant women (p = 0.04) compared to non-albicans Candida species. Almost all (98%) Candida albicans isolates were susceptible to fluconazole while all non-albicans Candida species were fluconazole resistant. STIs were diagnosed in 92 women (36%): 30 (12%) with C. trachomatis, 11 (4.3%) N. gonorrhoeae, and 70 (28%) T. vaginalis; 98 (39%) women had BV. Candida infection alone was diagnosed in 30 women (12%), combined with STIs in 42 women (17%) and was concurrent with BV in 38 women (15%). Candida infection was more often detected in swabs from women without C. trachomatis detected (6.4% vs. 16%; OR 0.30; 95% CI 0.10-0.77, p = 0.006). The high prevalence of Candida infection, especially those due to non-albicans Candida species that are resistant to fluconazole, is a great concern in our setting and may lead to poor treatment outcomes. Access to microbiological testing for Candida species in the context of syndromic management is warranted.
Sections du résumé
BACKGROUND
Vaginal discharge syndrome (VDS) is a common condition. Clinical management targets sexually transmitted infections (STIs) and bacterial vaginosis (BV); there is limited focus on Candida infection as cause of VDS. Lack of Candida treatment coverage and, if present, antifungal resistance may result in VDS treatment failure. This study aimed to determine the prevalence of Candida infection, antifungal resistance, and coinfections in Namibian women with VDS.
METHODS
A cross-sectional study was performed using 253 vaginal swabs from women with VDS in Namibia. Demographic data was collected, and phenotypic and molecular detection of Candida species was performed followed by fluconazole susceptibility testing of Candida isolates. BV was diagnosed using Nugent score microscopy; molecular detection of Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis was performed.
RESULTS
Candida species was detected in 110/253 women (43%). Ninety women (36%) had Candida albicans and 24 (9.5%) had non-albicans Candida species. The non-albicans species detected were 19 (17%) Candida glabrata, 4.0 (3.5%) Candida krusei, and 1.0 (0.9%) Candida parapsilosis. Candida albicans were more frequently isolated in younger (p = 0.004) and pregnant women (p = 0.04) compared to non-albicans Candida species. Almost all (98%) Candida albicans isolates were susceptible to fluconazole while all non-albicans Candida species were fluconazole resistant. STIs were diagnosed in 92 women (36%): 30 (12%) with C. trachomatis, 11 (4.3%) N. gonorrhoeae, and 70 (28%) T. vaginalis; 98 (39%) women had BV. Candida infection alone was diagnosed in 30 women (12%), combined with STIs in 42 women (17%) and was concurrent with BV in 38 women (15%). Candida infection was more often detected in swabs from women without C. trachomatis detected (6.4% vs. 16%; OR 0.30; 95% CI 0.10-0.77, p = 0.006).
CONCLUSIONS
The high prevalence of Candida infection, especially those due to non-albicans Candida species that are resistant to fluconazole, is a great concern in our setting and may lead to poor treatment outcomes. Access to microbiological testing for Candida species in the context of syndromic management is warranted.
Identifiants
pubmed: 35971143
doi: 10.1186/s13756-022-01143-6
pii: 10.1186/s13756-022-01143-6
pmc: PMC9377096
doi:
Substances chimiques
Antifungal Agents
0
Fluconazole
8VZV102JFY
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
104Informations de copyright
© 2022. The Author(s).
Références
Obstet Gynecol. 2017 Jul;130(1):181-189
pubmed: 28594779
Asian Pac J Trop Biomed. 2012 Apr;2(4):294-7
pubmed: 23569916
Infect Drug Resist. 2017 Jul 31;10:237-245
pubmed: 28814889
Afr Health Sci. 2020 Mar;20(1):51-58
pubmed: 33402892
J Clin Microbiol. 1991 Feb;29(2):297-301
pubmed: 1706728
Clin Infect Dis. 2021 May 4;72(9):1538-1543
pubmed: 32350529
J Infect Public Health. 2017 Jul - Aug;10(4):431-437
pubmed: 27422139
Afr J Med Med Sci. 2014 Sep;43(Suppl 1):23-28
pubmed: 26681823
Ann Med Health Sci Res. 2014 May;4(3):410-6
pubmed: 24971218
BMC Infect Dis. 2018 Oct 3;18(1):499
pubmed: 30285705
J Antimicrob Chemother. 2013 Apr;68(4):778-85
pubmed: 23221625
J Fungi (Basel). 2019 Aug 16;5(3):
pubmed: 31426392
Front Microbiol. 2021 Apr 28;12:655069
pubmed: 33995315
Ann Clin Microbiol Antimicrob. 2020 Jan 28;19(1):5
pubmed: 31992328
BMC Pregnancy Childbirth. 2019 Dec 30;19(1):527
pubmed: 31888537
Br Microbiol Res J. 2015;5(4):322-331
pubmed: 26594637
S Afr Med J. 2018 Oct 02;108(10):876-880
pubmed: 30421718
Pan Afr Med J. 2017 Dec 06;28:294
pubmed: 29854067
Trop Med Int Health. 2018 May;23(5):541-548
pubmed: 29505113
Front Microbiol. 2019 Jan 14;9:3270
pubmed: 30692972
PLoS One. 2021 Apr 20;16(4):e0250044
pubmed: 33878134
PLoS One. 2016 Oct 5;11(10):e0163365
pubmed: 27706174
Future Microbiol. 2018 Aug;13:1175-1191
pubmed: 30113223
Infect Dis Obstet Gynecol. 2012;2012:872169
pubmed: 22791958
Lancet Infect Dis. 2019 Jun;19(6):658-669
pubmed: 31031172
Infect Dis Obstet Gynecol. 2018 May 9;2018:3946862
pubmed: 29861622
J Infect Dis. 2017 Aug 15;216(suppl_3):S445-S451
pubmed: 28911043
J Mycol Med. 2018 Mar;28(1):186-192
pubmed: 28939305
Trop Med Int Health. 2016 Sep;21(9):1138-46
pubmed: 27350659
Infect Dis Obstet Gynecol. 2014;2014:387070
pubmed: 24812479
Sex Transm Dis. 2018 Jun;45(6):422-428
pubmed: 29465674
Sex Transm Infect. 2007 Apr;83(2):126-9
pubmed: 17090567
Niger J Clin Pract. 2018 Aug;21(8):1017-1022
pubmed: 30074004
Braz J Microbiol. 2017 Jan - Mar;48(1):145-150
pubmed: 27756539
Sex Transm Dis. 2016 Nov;43(11):698-705
pubmed: 27893600
BMC Res Notes. 2019 Nov 27;12(1):775
pubmed: 31775911
J Infect Dis. 2020 Mar 16;221(Suppl 2):S139-S147
pubmed: 32176789
BMC Infect Dis. 2016 Apr 23;16:180
pubmed: 27107961
BMC Womens Health. 2018 Jun 15;18(1):94
pubmed: 29902998
Geburtshilfe Frauenheilkd. 2015 Apr;75(4):355-366
pubmed: 26028693
Front Microbiol. 2022 Mar 17;13:808890
pubmed: 35369470
Rev Bras Ginecol Obstet. 2021 Aug;43(8):600-607
pubmed: 34547794
Can J Infect Dis Med Microbiol. 2016;2016:5930489
pubmed: 28058052
Sex Transm Infect. 2004 Feb;80(1):54-7
pubmed: 14755037
FEMS Microbiol Rev. 2012 Mar;36(2):288-305
pubmed: 21569057
Front Microbiol. 2016 Dec 15;7:1995
pubmed: 28018323
J Fungi (Basel). 2018 Oct 31;4(4):
pubmed: 30384449
Afr J Infect Dis. 2018 Mar 07;12(1 Suppl):90-94
pubmed: 29619437
J Mycol Med. 2018 Jun;28(2):345-348
pubmed: 29548876
BMC Pregnancy Childbirth. 2020 May 6;20(1):266
pubmed: 32375724
Infect Drug Resist. 2018 Mar 28;11:447-456
pubmed: 29628769
Can J Infect Dis Med Microbiol. 2019 Jan 22;2019:1672109
pubmed: 30805068
J Mycol Med. 2019 Dec;29(4):317-319
pubmed: 31481349
J Mycol Med. 2014 Jun;24(2):100-5
pubmed: 24746421